Business Description
Adlai Nortye Ltd
NAICS : 541714
SIC : 2834
ISIN : US00704R1095
Share Class Description:
ANL: ADRTotal Employee Number:
109Description
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 8.72 | |||||
Equity-to-Asset | 0.87 | |||||
Debt-to-Equity | 0.12 | |||||
Debt-to-EBITDA | -1.25 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -8.83 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 12.6 | |||||
3-Year EPS without NRI Growth Rate | 11.9 | |||||
3-Year FCF Growth Rate | 4.5 | |||||
3-Year Book Growth Rate | 68.8 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 36.56 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 61.11 | |||||
9-Day RSI | 60.27 | |||||
14-Day RSI | 59.7 | |||||
3-1 Month Momentum % | 26.36 | |||||
6-1 Month Momentum % | 48.65 | |||||
12-1 Month Momentum % | 647.46 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.55 | |||||
Quick Ratio | 9.55 | |||||
Cash Ratio | 9.23 | |||||
Days Sales Outstanding | 5.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.7 | |||||
Shareholder Yield % | 0.96 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -123.47 | |||||
Net Margin % | -124.77 | |||||
EBITDA Margin % | -118.03 | |||||
FCF Margin % | -186.56 | |||||
OCF Margin % | -186.56 | |||||
ROE % | -31.52 | |||||
ROA % | -19.05 | |||||
ROIC % | -58.39 | |||||
3-Year ROIIC % | -11.73 | |||||
ROC (Joel Greenblatt) % | -704.45 | |||||
ROCE % | -28.53 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 35.45 | |||||
PB Ratio | 4.55 | |||||
Price-to-Tangible-Book | 4.55 | |||||
EV-to-EBIT | -36.29 | |||||
EV-to-Forward-EBIT | -20.38 | |||||
EV-to-EBITDA | -36.29 | |||||
EV-to-Forward-EBITDA | -20.38 | |||||
EV-to-Revenue | 42.83 | |||||
EV-to-Forward-Revenue | 115.86 | |||||
EV-to-FCF | -22.96 | |||||
| Price-to-Net-Current-Asset-Value | 4.72 | |||||
| Price-to-Net-Cash | 4.92 | |||||
Earnings Yield (Greenblatt) % | -2.76 | |||||
FCF Yield % | -3.44 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ANL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adlai Nortye Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 18.056 | ||
| EPS (TTM) ($) | -0.66 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 654.39 | ||
| 14-Day RSI | 59.7 | ||
| 14-Day ATR ($) | 1.124393 | ||
| 20-Day SMA ($) | 14.16325 | ||
| 12-1 Month Momentum % | 647.46 | ||
| 52-Week Range ($) | 0.8786 - 17.25 | ||
| Shares Outstanding (Mil) | 64.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adlai Nortye Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adlai Nortye Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| General meeting for 2025 | 2026-09-14 | In 3 days | ||
| Second quarter earnings results for 2025 | 2026-08-14 | 12.86 (-2.43%) | ||
| Annual report for 2025 | 2026-04-10 | 12.00 (+1.78%) | ||
| Annual report for 2024 | 2025-04-30 | 1.98 (-1.00%) | ||
| Fourth quarter earnings results for 2025 | 2025-04-30 | 1.98 (-1.00%) |
Show
Entries
Adlai Nortye Ltd Frequently Asked Questions
What is Adlai Nortye Ltd(ANL)'s stock price today?
The current price of ANL is $15.21. The 52 week high of ANL is $17.25 and 52 week low is $0.88.
When is next earnings date of Adlai Nortye Ltd(ANL)?
The next earnings date of Adlai Nortye Ltd(ANL) is 2027-08-13 Est..
Does Adlai Nortye Ltd(ANL) pay dividends? If so, how much?
Adlai Nortye Ltd(ANL) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Headlines
See More- 1
Sep 01, 2026
Quant Check: Top- and bottom-rated small-cap healthcare stocks post-earnings
Seeking Alpha • 9:25am
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers